Coherus Announces U.S. Launch of LOQTORZI™
– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy –
– Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing chemotherapy, irrespective of PD-L1 status –
Related news for (CHRS)
- Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Coherus Divesting UDENYCA Franchise to Intas Pharmaceuticals for up to $558M
- Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium